AUTH/3820/9/23: Complainant v Daiichi Sankyo (AI recording of HCP calls) – No breach

📅 2023 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/3820/9/23
PartiesComplainant v Daiichi Sankyo UK Ltd
IssueAlleged covert recording of calls with health professionals by representatives using an AI digital tool
ComplainantAnonymous, non-contactable
Applicable Code2021
Clauses considered5.1, 15.5, 15.6
Company positionRecordings only with HCP consent; tool used for coaching/quality, not promotion; audio anonymised and deleted after analysis; pilot ceased 14 September 2023
Panel decisionNo breach of Clauses 5.1, 15.5 and 15.6
Complaint received08 September 2023
Case completed11 October 2024
AppealNo appeal
SanctionsNone

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • An anonymous, non-contactable complainant alleged Daiichi Sankyo was using AI technology to record healthcare professional (HCP) calls “covertly”, stating it was for representative training.
  • Daiichi Sankyo explained it had piloted a digital tool (app) with 13 sales representatives to analyse call quality for coaching and development.
  • The company said HCP consent was required before any recording; if an HCP resisted, the tool was not used and no recording took place.
  • Daiichi Sankyo stated 20 calls were recorded with verbal consent; five doctors reportedly did not consent.
  • The company stated the tool focused predominantly on the representative voice, anonymised and extracted keywords for analysis, and the audio was securely deleted once analysis was complete.
  • Daiichi Sankyo ceased use of the tool as of 14 September 2023.
  • The PMCPA asked Daiichi Sankyo to consider Clauses 5.1, 15.5 and 15.6 of the 2021 Code.
⚖️

Outcome

  • No breach of Clause 5.1.
  • No breach of Clause 15.5.
  • No breach of Clause 15.6.
  • No appeal.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training